Initial in vivo feasibility of a pre-clinical focused ultrasound system applied to blood-brain barrier opening in monkeys

The blood-brain barrier (BBB) is a selective barrier within the neurovascular unit formed by the endothelial cells that line cerebral microvessels that impedes entry of all large and the vast majority of small molecules including the most potent CNS disease therapeutic agents from entering from the lumen into the brain parenchyma. Microbubble-enhanced, focused ultrasound (ME-FUS) has been previously shown to disrupt noninvasively, selectively, and transiently the BBB in small animals in vivo. The study addresses the focusing properties of single - element transducers at intermediate frequencies (500 kHz) through primate and human skulls, targeting clinically relevant targets extracted from 3D brain atlases such as the hippocampus and the basal ganglia, which are typically affected by early Alzheimer's and Parkinson's disease, respectively. A preliminary in vivo study was performed to study the frequency dependence of BBB opening parameters in mice. Then, feasibility of transcranial ME-FUS BBB opening in non-human primates was demonstrated with subsequent BBB recovery. Sonications were combined with two different types of microbubbles (custom made 4-5 μm and Definity®). 3T MRI was used to confirm the BBB disruption and to assess brain damage.

[1]  Brian K. Fiske,et al.  Special focus section: Gene therapy for Parkinson's disease , 2008, Experimental Neurology.

[2]  E. Konofagou,et al.  FEASIBILITY STUDY OF A CLINICAL BLOOD-BRAIN BARRIER OPENING ULTRASOUND SYSTEM. , 2010, Nano LIFE.

[3]  I. Romero,et al.  Transporting therapeutics across the blood-brain barrier. , 1996, Molecular medicine today.

[4]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[5]  R. Mandel CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. , 2010, Current opinion in molecular therapeutics.

[6]  James J. Choi,et al.  Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice. , 2007, Ultrasound in medicine & biology.

[7]  V. Ferrera,et al.  Noninvasive, Transient and Selective Blood-Brain Barrier Opening in Non-Human Primates In Vivo , 2011, PloS one.

[8]  K. Hynynen,et al.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.

[9]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[10]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[11]  John H. Zhang,et al.  Optison (FS069) Disrupts the Blood-Brain Barrier in Rats , 2000, Anesthesia and analgesia.

[12]  B. Engelhardt Development of the blood-brain barrier , 2003, Cell and Tissue Research.